Cardiff Oncology, Inc.

CRDF

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001213037

D

fourth fifth of 369 graded peers in healthcare

rank 236 of 369; percentile 63.9; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard

Profitability	B/C	percentile 41.2
Solvency	D	percentile 64.4
Growth and financing	C	percentile 52.6
Reliability	0.83 AUC	filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets	total assets $61.9M
Standard universe	outside	revenue above $1M and assets above $10M
Warnings	short runway; fortress balance sheet	
Inputs computable	7 of 14	
Graded from	filings received through Feb 24, 2026	262 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$0.73	2026-11-12; market equity $56.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 41.2						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				
required facts have no common fiscal period end						
Accruals ratio	(10.0%)	(6.6%)		41.2	800	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Solvency, sleeve percentile 64.4						
Twelve-month failure probability	0.32%	0.08%	69.9	247	2026-09-30	
Altman Z double-prime	(20.45)	(0.35)	74.3	744	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
interest expense must exceed $100,000						
Current ratio	3.67x	2.95x	49.1	826	2025-12-31	
Growth and financing, sleeve percentile 52.6						
Revenue growth, three-year compound	15.4%	10.1%	39.2	412	2025-12-31	
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	(18.9%)	2.2%	82.5	694	2025-12-31	
Net share issuance, one year	2.8%	2.5%	36.1	627	2026-02-19	

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.6 months
Fortress balance sheet	cash minus debt is 8,225,764 USD; Altman Z is not used

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
231	Lenz Therapeutics, Inc. (LENZ)	62.5	C/D	short runway
232	AbbVie Inc. (ABBV)	62.8	D	
233	Perspective Therapeutics, Inc. (CATX)	63.0	D	dilution, short runway, fortress balance sheet
234	Iovance Biotherapeutics, Inc. (IOVA)	63.3	D	dilution, short runway
235	Royalty Pharma plc (RPRX)	63.6	D	
236	Cardiff Oncology, Inc. (CRDF)	63.9	D	short runway, fortress balance sheet
237	Integra Lifesciences Holdings Corp. (IART)	64.1	D	
238	AbCellera Biologics Inc. (ABCL)	64.4	D	
239	Arvinas, Inc. (ARVN)	64.7	D	fortress balance sheet
240	Organogenesis Holdings Inc. (ORGO)	64.9	D	fortress balance sheet
241	AIM ImmunoTech Inc. (AIM)	65.2	D	late filer, degenerate inputs, distress

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(48.5%)	(1.9%)	15
Distance from 52-week high	(77.3%)	(30.8%)	10
EBIT to enterprise value	(109.9%)	(1.9%)	9
Free cash flow yield	(67.1%)	(1.0%)	10
Book value to price	0.50	0.28	68
Sales to price	0.01	0.29	6
Composite equity issuance, five years	74.2%	20.5%	71
Relative strength against the sector, log excess return	(0.83)	(0.19)	15

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$12.1M
Operating cash flow, four quarters	-$39.9M
Months of runway	3.6
Days since last periodic filing	1 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$508,077

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$244,632	2019-12-31	2021-02-25	10-K	21-003277
2	cost of revenue	us-gaap:CostOfRevenue	$0	2019-12-31	2020-02-27	10-K	20-002424
3	assets	us-gaap:Assets	$13.1M	2019-12-31	2021-02-25	10-K	21-003277
4	net income	us-gaap:NetIncomeLoss	-$45.9M	2025-12-31	2026-02-24	10-K	26-067464
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$37.9M	2025-12-31	2026-02-24	10-K	26-067464
6	assets	us-gaap:Assets	$61.9M	2025-12-31	2026-02-24	10-K	26-067464
7	assets	us-gaap:Assets	$97.2M	2024-12-31	2026-02-24	10-K	26-067464
8	revenue	us-gaap:SalesRevenueNet	$378,325	2018-12-31	2019-03-06	10-K	19-002546
9	cost of revenue	us-gaap:CostOfRevenue	$597,457	2018-12-31	2020-02-27	10-K	20-002424
10	revenue	us-gaap:SalesRevenueNet	$505,404	2017-12-31	2019-03-06	10-K	19-002546
11	cost of revenue	us-gaap:CostOfRevenue	$1.8M	2017-12-31	2019-03-06	10-K	19-002546
12	revenue	us-gaap:SalesRevenueNet	$381,072	2016-12-31	2018-02-26	10-K	18-002226
13	cost of revenue	us-gaap:CostOfRevenue	$1.7M	2016-12-31	2018-02-26	10-K	18-002226
14	revenue	us-gaap:SalesRevenueNet	$312,812	2015-12-31	2017-03-15	10-K	17-002601
15	cost of revenue	us-gaap:CostOfRevenue	$629,191	2015-12-31	2017-03-15	10-K	17-002601
16	current assets	us-gaap:AssetsCurrent	$60.1M	2025-12-31	2026-02-24	10-K	26-067464
17	current liabilities	us-gaap:LiabilitiesCurrent	$16.4M	2025-12-31	2026-02-24	10-K	26-067464
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$430.0M	2025-12-31	2026-02-24	10-K	26-067464

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating income	us-gaap:OperatingIncomeLoss	-$49.0M	2025-12-31	2026-02-24	10-K	26-067464
20	book equity	us-gaap:StockholdersEquity	$45.4M	2025-12-31	2026-02-24	10-K	26-067464
21	liabilities	us-gaap:Liabilities	$16.5M	2025-12-31	2026-02-24	10-K	26-067464
22	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$0	2017-12-31	2018-02-26	10-K	18-002226
23	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$8.2M	2017-12-31	2019-03-06	10-K	19-002546
24	operating income	us-gaap:OperatingIncomeLoss	-$25.6M	2017-12-31	2019-03-06	10-K	19-002546
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$1.2M	2017-12-31	2019-03-06	10-K	19-002546
26	operating income	us-gaap:OperatingIncomeLoss	-$28.9M	2021-12-31	2023-03-02	10-K	23-006037
27	interest expense	us-gaap:InterestExpense	$0	2021-12-31	2022-02-24	10-K	22-003808
28	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$593,000	2025-12-31	2026-02-24	10-K	26-067464
29	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$683,000	2024-12-31	2026-02-24	10-K	26-067464
30	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$488,000	2023-12-31	2025-02-27	10-K	25-028992
31	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$386,000	2022-12-31	2024-02-29	10-K	24-007948
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$44,000	2025-12-31	2026-02-24	10-K	26-067464
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$37.7M	2024-12-31	2026-02-24	10-K	26-067464
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$80,000	2024-12-31	2026-02-24	10-K	26-067464
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$30.9M	2023-12-31	2025-02-27	10-K	25-028992
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$582,000	2023-12-31	2025-02-27	10-K	25-028992
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$33.8M	2022-12-31	2024-02-29	10-K	24-007948
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.0M	2022-12-31	2024-02-29	10-K	24-007948
39	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$364,000	2025-12-31	2026-02-24	10-K	26-067464
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$45.9M	2025-12-31	2026-02-24	10-K	26-067464
41	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-02-24	10-K	26-067464
42	current assets	us-gaap:AssetsCurrent	$95.1M	2024-12-31	2026-02-24	10-K	26-067464
43	current liabilities	us-gaap:LiabilitiesCurrent	$13.4M	2024-12-31	2026-02-24	10-K	26-067464
44	assets	us-gaap:Assets	$81.6M	2023-12-31	2025-02-27	10-K	25-028992
45	assets	us-gaap:Assets	$116.2M	2022-12-31	2024-02-29	10-K	24-007948
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,364,979	2026-02-19	2026-02-24	10-K	26-067464
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	66,524,294	2025-02-20	2025-02-27	10-K	25-028992

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.